Reports say Merck is in discussions to acquire Revolution Medicines in a **$28B–$32B** range (not finalized; other bidders may be interested).
If it happens, it’s a rare mega-cap pre-commercial move that could reset oncology comp expectations for RAS-pathway platforms — and shift focus to bid/antitrust/timing risk as much as clinical readouts.
Want to stay up to date? I write a free daily newsletter (link in bio)
For those following the space: what’s the most plausible “endgame” structure here (single bidder, competitive process, or talks fizzle)?